The first all-oral regimen for treating the hepatitis C virus has been approved by the US FDA. Gilead Science's sofosbuvir was given unanimous backing by the 15 members of the panel.
Read our coverage of this treatment development here:
The first all-oral regimen for treating the hepatitis C virus has been approved by the US FDA. Gilead Science's sofosbuvir was given unanimous backing by the 15 members of the panel.
Read our coverage of this treatment development here: